Benzinga · Jul 30, 2026
BGM Group Announces Chairman And Co-CEO Chen Xin Resigns, Effective July 30, 2026; Zhanchang Xin Appointed As New Chairman Of Board; Hong Li Named As Co-Chief Executive Officer
-SEC Filing
BG
NASDAQ · BGM
BGM Group Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic
$0.30
Down-$0.01 (-2.45%)
Updated Aug 15, 2026, 12:11 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.18B
- P/E ratio
- -29.55
- Dividend yield
- 0.00%
- 52-week range
- $0.25 – $1.08
- Volume
- 19.51K
- Avg. volume
- 36.41K
Price performance
BGM price history
1M range · 20 trading sessions · Daily adjusted prices
BGM closed at $0.30 after 20 trading sessions, up 5.96% for the selected period.
- Last close
- $0.30
- Period change
- +5.96%
- Period low
- $0.27
- Period high
- $0.30
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $0.296 | $0.3003 | $0.286 | $0.2985 | 19.51K |
| Aug 12, 2026 | $0.2987 | $0.3185 | $0.28 | $0.2884 | 121.51K |
| Aug 11, 2026 | $0.30 | $0.30 | $0.29 | $0.291 | 40.35K |
| Aug 10, 2026 | $0.2995 | $0.3095 | $0.2958 | $0.2971 | 23.22K |
| Aug 7, 2026 | $0.31 | $0.31 | $0.2962 | $0.3004 | 20.1K |
| Aug 6, 2026 | $0.305 | $0.305 | $0.292 | $0.2961 | 12.46K |
| Aug 5, 2026 | $0.3032 | $0.304 | $0.297 | $0.2971 | 53.1K |
| Aug 4, 2026 | $0.299 | $0.3045 | $0.2871 | $0.3032 | 31.11K |
| Aug 3, 2026 | $0.285 | $0.304 | $0.2778 | $0.291 | 100.48K |
| Jul 31, 2026 | $0.2669 | $0.3039 | $0.2669 | $0.282 | 47.55K |
| Jul 30, 2026 | $0.2866 | $0.2866 | $0.2636 | $0.2718 | 24.37K |
| Jul 29, 2026 | $0.2851 | $0.2933 | $0.285 | $0.2865 | 13.46K |
| Jul 28, 2026 | $0.285 | $0.3048 | $0.285 | $0.285 | 17.22K |
| Jul 27, 2026 | $0.305 | $0.305 | $0.285 | $0.2853 | 36.58K |
| Jul 24, 2026 | $0.30 | $0.305 | $0.285 | $0.2897 | 46.07K |
| Jul 23, 2026 | $0.273 | $0.3049 | $0.273 | $0.2907 | 20.26K |
| Jul 22, 2026 | $0.2901 | $0.3092 | $0.273 | $0.2811 | 35.03K |
| Jul 21, 2026 | $0.253 | $0.315 | $0.2521 | $0.30 | 125.66K |
| Jul 20, 2026 | $0.296 | $0.296 | $0.25 | $0.2747 | 52.22K |
| Jul 17, 2026 | $0.3001 | $0.307 | $0.2765 | $0.2817 | 50.46K |
Latest BGM news
The latest Smart Investors Daily articles mentioning BGM.
Stock researchCompany · Overview
BGM research
Overview
Company profile and research snapshot.
Company profile
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Feb 26, 2026
BGM Group Receives Nasdaq Noncompliance Notice, Gets 60 Days To Regain Compliance
BGM Group Ltd. (NASDAQ: BGM) (the "Company" or "BGM") announced on February 24, 2026, that it has received a notification (the "Notification") from the Listing Qualifications Department of The Nasdaq Stock Market
seekingalpha.com · Sep 24, 2025
BGM Group: I Think I Found An Undervalued Stock
32.7% of BGM's revenue is now from high-growth AI, pushing profit up 78%. Yet, the market still values it like a slow-moving API business. With β ≈ 0.04–0.05 and basically no leverage, you get CAPM ≈ 4.42% and WACC ≈ 4.41%, that math checks out. On my assumptions, the DCF lands at about $19.07 per share. Versus the current $8.93, that's roughly +113% upside—consistent with the "undervalued" call.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
